• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Dermatology

Bayer eyes $1B sale of medical skin cream business

October 13, 2016 By Sarah Faulkner

(Reuters) — Bayer (ETR:BAYN) has short-listed India’s Lupin (NSE:LUPIN) and investor BC Partners as prospective buyers of medical skin cream assets in a potentially €1 billion ($1.1 billion) deal, several people familiar with the sale told Reuters. Germany’s Bayer has for more than 2 years sought to narrow the focus of its healthcare division and its planned $66 billion Monsanto […]

Filed Under: Cosmetic/Aesthetic, Mergers & Acquisitions, Wall Street Beat Tagged With: Bayer, Dermatology, Lupin Pharmaceutical

Sensus Healthcare postpones IPO

March 30, 2016 By Brad Perriello

Sensus Healthcare reportedly postponed its initial public offering today, after setting terms earlier this month with a midpoint raise of $20 million. Boca Raton, Fla.-based Sensus makes the SRT-100 and SRT-100 Vision photon X-ray low-energy superficial radiotherapy systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas. The company said March 9 that it planned […]

Filed Under: Funding Roundup, Initial Public Offering (IPO) Tagged With: Dermatology, Sensus Healthcare LLC

Mela Sciences recalls MelaFind

May 27, 2015 By Fink Densford Leave a Comment

Mela Sciences recalls MelaFind device

Mela Sciences (NSDQ:MELA) recalled its flagship MelaFind melanoma diagnosis aid because some of its software wasn’t included in its pre-market approval from the FDA.

Filed Under: Diagnostics, Food & Drug Administration (FDA), News Well, Recalls Tagged With: Dermatology, MELA Sciences Inc.

Smith & Nephew gets in on Michelson Diagnostics Series B round

February 16, 2015 By Brad Perriello Leave a Comment

Smith & Nephew gets in on Michelson Diagnostics Series B round

Filed Under: Funding Roundup, News Well Tagged With: Dermatology, Michelson Diagnostics, Smith & Nephew

Derma Sciences skins out $36M

December 12, 2012 By MassDevice staff Leave a Comment

Derma Sciences

Derma Sciences (NSDQ:DSCI) said it’s closed an offering of some 3.5 million shares of its stock at $10.34 apiece.

The Princeton, N.J.-based medical device company said it plans to use the $33.8 million in net proceeds from the $36.4 million offering to further develop its lead drug candidate DSC127.

Derma Sciences said the drug is being designed to treat chronic diabetic foot ulcers.

Filed Under: Funding Roundup, News Well Tagged With: Derma Sciences Inc., Dermatology

MassDevice.com +3 | The top 3 med-tech stories for March 22, 2012.

March 22, 2012 By MassDevice staff Leave a Comment

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you’re still in the know with MassDevice +3.

Filed Under: News Well, Wall Street Beat Tagged With: Cardiac Rhythm Management, Dermatology, MELA Sciences Inc.

Mela Sciences’ Joe Gulfo on returning to the market in the shadow of the medical device tax

March 22, 2012 By Arezu Sarvestani Leave a Comment

Mela Sciences logo

Mela Sciences (NSDQ:MELA) CEO Joe Gulfo tells MassDevice that he feels like a kid in a candy store as he takes the company back to market – and not even the ever-looming burden of the medical device tax can dampen his enthusiasm.

Filed Under: Diagnostics, News Well, Oncology, Wall Street Beat Tagged With: Dermatology, MELA Sciences Inc.

SBi secures $43M loan | Funding Roundup

December 9, 2011 By MassDevice staff Leave a Comment

Star ankleStar total ankle replacement

Orthopedic technology company Small Bone Innovations Inc. landed a $43 million loan to further sales of its flagship ankle replacement device.

The New York-based company plans to use the credit facility as working capital to drive U.S. growth of its Star total ankle replacement, a non-cemented implant designed to replace arthritic ankle joints in patients with osteoarthritis, post-traumatic arthritis or rheumatoid arthritis.

The system is currently the only mobile-bearing total ankle replacement approved for the U.S. market.

Filed Under: Funding Roundup, Implants, News Well, Orthopedics Tagged With: Cleveland Clinic, Dermatology, Direct Flow Medical Inc., Edwards Lifesciences, Hansen Medical Inc., Harbor MedTech, Small Bone Innovations Inc.

What’s up with Mela Sciences? | Wall Street Beat

November 4, 2011 By MassDevice staff Leave a Comment

Mela Sciences

If the FDA grants clearance and no-one hears, did it really happen?

That might be the question of the day for Mela Sciences (NSDQ:MELA) and CEO Dr. Joseph Gulfo, as they try to comprehend a 15.4 percent share price plunge, despite a long-awaited approval granted by the federal watchdog agency just a few days ago.

Filed Under: News Well, Oncology, Spine, Wall Street Beat Tagged With: Dermatology, MELA Sciences Inc., Nuvasive

Mela Sciences CEO: MelaFind rollout planned for early 2012

November 3, 2011 By Emily Greenhalgh Leave a Comment

Dr. Joseph Gulfo, CEO of Mela Sciences (NSDQ:MELA), says the company plans to begin rolling out its MelaFind skin cancer detection system during the first quarter of 2012, after winning a hard-earned green-light from the FDA.

"I don’t think we’ll be ‘selling,’ in the classic sense of selling, for at least a year and a half," Gulfo told MassDevice. "Dermatologists want this system, so we don’t need to ‘sell’ it.

Filed Under: Food & Drug Administration (FDA), News Well, Oncology, Pre-Market Approval (PMA) Tagged With: Dermatology, MELA Sciences Inc.

Mela shares double overnight after positive FDA review

November 19, 2010 By MassDevice staff Leave a Comment

MELA logo

Mela Sciences Inc.’s (NSDQ:MELA) stock doubled in price overnight after the a Food & Drug Administration panel voted in favor of its melanoma-detecting device’s safety and efficacy.

MELA shares were up 105.5 percent to $5.24 before the trading day opened. Through yesterday’s close, the shares lost 60 percent of their value in the past three months. The company’s shares’ gain remained around 95 percent up in mid-morning trading.

Filed Under: Business/Financial News, Diagnostics, News Well, Oncology Tagged With: Dermatology, MELA Sciences Inc.

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS